Nowosci z ESC cz. 5
Wygladaan to, ze prasugrel nie jest lepszy od klopidogrelu u pacjentow z ostrymi zespolami wiencowymi, nieleczonymi interwencyjnie.
n TRILOGY ACS, one of the few studies to focus on high-risk patients with acute coronary syndrome (ACS) who are medically managed without revascularization, the newer antiplatelet agent prasugrel (Effient, Lilly/Daiichi-Sanyo) has failed to show a reduction in major cardiovascular events compared with clopidogrel [1]. The results were reported here at the European Society of Cardiology (ESC) 2012 Congress by Dr Matthew Roe (Duke Clinical Research Institute, Durham, NC), who is also lead author of the simultaneous online publication in the New England Journal of Medicine.
Dr Magnus Ohman
"This trial does not suggest a priori that prasugrel should be used for medically managed patients, because the results are neutral," senior author Dr Magnus Ohman (Duke Clinical Research Institute) told heartwire in an interview. Ohman discu...
n TRILOGY ACS, one of the few studies to focus on high-risk patients with acute coronary syndrome (ACS) who are medically managed without revascularization, the newer antiplatelet agent prasugrel (Effient, Lilly/Daiichi-Sanyo) has failed to show a reduction in major cardiovascular events compared with clopidogrel [1]. The results were reported here at the European Society of Cardiology (ESC) 2012 Congress by Dr Matthew Roe (Duke Clinical Research Institute, Durham, NC), who is also lead author of the simultaneous online publication in the New England Journal of Medicine.
Dr Magnus Ohman
"This trial does not suggest a priori that prasugrel should be used for medically managed patients, because the results are neutral," senior author Dr Magnus Ohman (Duke Clinical Research Institute) told heartwire in an interview. Ohman discu...
Pełna treść dotępna tylko dla zalogowanych użytkowników.
Nie masz jeszcze konta, zarejestruj się »